Skip to main content
    C

    Cognition Therapeutics Inc (CGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.73
    -0.04 (-5.68%)

    Market Cap: $76.24M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(14/21)
    Avg Surprise
    -201.12%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.07 - $-0.06
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07+8.0%
    60d ago$-0.07+4.7%
    30d ago$-0.070.0%
    7d ago$-0.070.0%
    Current$-0.07
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.22 - $-0.00
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.07---
    Jun 26
    Reported Aug 6
    		$-0.04$-0.06+33.33%Beat+63.6%
    Mar 26
    Reported May 7
    		$-0.05$-0.07+28.57%Beat+64.3%
    Dec 25
    Reported Mar 26
    		$-0.02N/A+74.19%Beat+89.4%
    Sep 25
    Reported Nov 6
    		$-0.06$-0.11+45.45%Beat+76.0%
    Jun 25
    Reported Aug 7
    		$-0.11$-0.12+8.33%Beat+38.9%
    Mar 25
    Reported May 7
    		$-0.14$-0.11-27.27%Miss+48.1%
    Dec 24
    Reported Mar 20
    		$-0.19$-0.17-11.00%Miss+30.1%
    Sep 24
    Reported Nov 13
    		$-0.25$-0.21-19.05%Miss-13.6%
    Jun 24
    Reported Aug 8
    		$-0.18$-0.23+21.74%Beat-12.5%
    Mar 24
    Reported May 7
    		$-0.27$-0.24-12.50%Miss-28.6%
    Dec 23
    Reported Mar 26
    		$-0.27$-0.34+20.59%Beat-35.0%
    Sep 23
    Reported Nov 2
    		$-0.22$-0.29+24.14%Beat+24.1%
    Jun 23
    Reported Aug 8
    		$-0.16$-0.21+23.81%Beat+36.0%
    Mar 23
    Reported May 4
    		$-0.21$-0.18-16.67%Miss-23.5%
    Dec 22
    Reported Mar 23
    		$-0.20$-0.30+33.33%Beat+98.3%
    Sep 22
    Reported Nov 14
    		$-0.29$-0.32+9.38%Beat-61.1%
    Jun 22
    Reported Aug 9
    		$-0.25$-0.32+21.88%Beat+56.9%
    Mar 22
    Reported May 11
    		$-0.17$-0.29+41.38%Beat+96.4%
    Dec 21
    Reported Mar 30
    		$-11.74$-0.26-4415.38%Miss-613.7%
    Sep 21
    Reported Oct 8
    		$-0.18N/A+68.42%Beat+96.8%
    Jun 21
    Reported Jul 19
    		$-0.58$-0.21-176.19%Miss+92.3%
    Mar 21
    Reported Jun 30
    		$-4.77$0.00N/AMiss-
    Dec 20
    Reported Mar 30
    		$-1.64$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-5.59$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-7.58$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.31EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-83.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.03xQuick Ratio7.03x
    Trading Statistics
    Beta1.80Avg Volume599.38K
    52-Week High$1.9352-Week Low$0.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.87
    SMA 20$0.91
    SMA 50$0.98
    SMA 200$1.10
    EMA 10$0.85
    EMA 20$0.90
    EMA 50$0.96
    EMA 200$1.08

    MACD

    Line: -0.05Signal: -0.04Hist: -0.02

    ADX

    ADX: 25.0+DI: 9.1-DI: 34.0

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down100.0
    PSAR$0.91

    Bollinger Bands

    Upper Band$1.06
    Lower Band$0.76
    %B Position3285%(Upper)
    Band Width-0.10

    RSI (14-Day)

    Oversold
    22.3

    Momentum Oscillators

    Stoch %K8.3
    Stoch %D9.9
    Williams %R-95.3
    ROC (10d)-17.8%
    Momentum-0.16
    CCI (20d)-231.9
    MFI (14d)14.9

    Volatility Measures

    ATR (14d)$0.06(7.9%)
    StdDev (20d)0.08
    Hist Vol45.2%(High)

    Volume Flow

    VWAP$0.74
    OBV382.9M
    AD Line-200.8M
    CMF (20d)-0.610

    Volume Metrics

    Avg Vol (20d)601.9K
    Vol Ratio1.1x
    VWMA (20d)$0.88

    Pivot Points

    R3$0.85
    R2$0.83
    R1$0.80
    Pivot Point$0.79
    S1$0.76
    S2$0.74
    S3$0.71

    Advanced Oscillators

    TSI-33.56
    Ultimate Osc22.6
    KST-128.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$250,000$0$0$0$372,000$0
    Cost of Revenue$0$0$61,000$0$0$0$71,000$0$0$0$66,000$0
    Gross Profit$0$0$-61,000$0$0$0$-71,000$0$0$0$306,000$0
    Operating Expenses$7.74M$8.82M$13.67M$6.38M$13.98M$13.78M$10.72M$14.46M$14.68M$14.10M$15.19M$14.74M
    R&D$5.10M$6.12M$11.15M$3.77M$11.48M$10.79M$8.15M$11.39M$11.58M$10.55M$11.60M$11.67M
    SG&A$2.64M$2.70M$2.52M$2.60M$2.50M$2.99M$2.57M$3.07M$3.10M$3.55M$3.59M$3.08M
    Operating Income$-7,738,000$-8,817,000$-13,671,000$-6,375,000$-13,978,000$-13,775,000$-10,723,000$-14,463,000$-14,678,000$-14,102,000$-15,189,000$-14,745,000
    Interest Income$-3,000$-5,000$-5,000$0$-3,000$-5,000$-5,000$-3,000$-7,000$-10,000$0$-2,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,935,000$-4,575,000$-3,348,000$-4,930,000$-6,737,000$-8,485,000$-7,847,000$-9,940,000$-7,048,000$-9,161,000$-8,150,000$-6,751,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,935,000$-4,575,000$-3,343,000$-4,930,000$-6,737,000$-8,485,000$-7,842,000$-9,937,000$-7,041,000$-9,151,000$-8,141,000$-6,749,000
    EBITDA$-3,877,000$-4,502,000$-3,282,000$-4,869,000$-6,673,000$-8,435,000$-7,771,000$-9,867,000$-6,974,000$-9,093,000$-8,075,000$-6,684,000
    EBIT$-3,932,000$-4,570,000$-3,343,000$-4,930,000$-6,734,000$-8,480,000$-7,842,000$-9,937,000$-7,041,000$-9,151,000$-8,141,000$-6,749,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CGTX

    News

    Cognition Therapeutics receives patent for zervimesine form By Investing.com

    Cognition Therapeutics, Inc. (NASDAQ:CGTX) has been granted a U.S. patent for a crystalline form of zervimesine, its lead drug candidate for neurodegenerative disorders. This patent...

    Investing.com South Africa•10/13/26•Bullish

    Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development

    Cognition Therapeutics, Inc. has been granted a US patent for a new crystalline form of its investigational drug zervimesine (CT1812)...

    Yahoo Finance•10/13/26•Bullish

    USPTO grants Cognition Therapeutics patent for zervimesine through 2045

    Cognition Therapeutics has been granted a U.S. patent for a novel crystalline form of its lead drug candidate, zervimesine (CT1812)...

    StreetInsider•10/13/26•Bullish

    A drug patent runs to 2045. FDA approval may allow up to five more years.

    Cognition Therapeutics (CGTX) has secured a U.S. patent for a new crystalline form of its lead drug candidate, zervimesine (CT1812)...

    Stock Titan•10/13/26•Bullish

    Cognition Therapeutics receives patent for zervimesine form

    Cognition Therapeutics (NASDAQ:CGTX) has been granted a U.S. patent for a crystalline form of its lead drug candidate, zervimesine, which is used for neurodegenerative disorders. The patent, set to expire in 2045...

    Investing.com•10/13/26•Bullish

    CGTX Valuation and Fair Value

    P/E
    -4.3x
    P/B
    2.0x
    See GNG's fair value

    CGTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -83.8%

    CGTX Competitors

    CompanyTicker
    NeOnc Technologies Holdings, Inc. Common StockNTHI
    Electrocore LLCECOR
    Nutriband IncNTRB
    InterCure Ltd.INCR
    Telomir Pharmaceuticals, Inc. Common StockTELO
    CareCloud, Inc.CCLD
    Pelthos Therapeutics Inc.PTHS
    LENSAR IncLNSR

    Sector: Healthcare

    CGTX Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CGTX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    16.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About CGTX

    Does CGTX pay dividends?

    Cognition Therapeutics Inc (CGTX) does not currently pay a regular dividend.

    What is CGTX's market cap?

    Cognition Therapeutics Inc (CGTX) has a market capitalization of $76.24M with a current stock price of $0.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In